RxDoctor Payments Data

Lisa Donofrio, NP

Psychiatric/Mental Health · Rochester, NYNPI 1154933745

Payments from drug & device makers

$6,343in general payments, 2019–2025

Across 350 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$902
  • Neurocrine Biosciences, Inc.$876
  • Teva Pharmaceuticals USA, Inc.$842
  • Takeda Pharmaceuticals U.S.A., Inc.$326
  • Otsuka America Pharmaceutical, Inc.$322
  • plus $2K from 11 others

What the payments were for

  • Food & beverage$6,21298%
  • Education$1322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,343 in reported general payments places this provider in the 90th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$11,356
Medicare patients
13
Services billed
146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl16$21,652
TrintellixVortioxetine Hydrobromide21$19,101
Bupropion XlBupropion Hcl173$3,951
Desvenlafaxine Succinate ErDesvenlafaxine Succinate15$1,885
Aripiprazole53$1,567
Duloxetine Hcl46$1,505
Vilazodone Hcl24$1,380
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine33$1,280
Escitalopram Oxalate68$967
Clonazepam116$952
Buspirone Hcl59$917
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine22$807
Venlafaxine Hcl14$619
Quetiapine Fumarate ErQuetiapine Fumarate20$619
Trazodone Hcl64$611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,504$21,65216 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$326$19,10121 claims
Almatica Pharma LLCSertraline Hcl$16$21944 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →